Consistent with our translational data which pointed to a pathogenic role of IL‐17A in HS, the current Phase II study demonstrated clinical efficacy of anti‐IL‐17A therapy with CJM112 in the treatment of moderate‐to‐severe HS. Here, IL17A is linked to histiocytic sarcoma.